CTIS2022-501682-45-00招募中1 期
The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction
niversity Hospital Maastricht0 个研究点目标入组 48 人开始时间: 2022年8月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •HFpEF diagnosis according to the ESC 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure, Ability to understand and speak the Dutch language, Treatment with empagliflozin 10mg once daily is planned to be started by the treating physician, Signed informed consent
排除标准
- •Unable or unwilling to sign informed consent, Under 18 years of age, Contra-indication to the use of empagliflozin, Use of empagliflozin or other SGLT-2 inhibitor at baseline, Insulin dependent patients (Fasting conditions cause a risk of ketoacidosis in these patients), Subjects currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study, Any condition that interferes with the correct execution of the LASCA measurements (patient is unable to keep arms motionless during the measurements, any condition that does not allow disposables to be attached to the forearm skin), Any other reason that makes it undesirable for patient to use empagliflozin according to the researcher / treating physician
研究者
相似试验
招募中
4 期
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection FractionMicrovascular DysfunctionNCT06046612Maastricht University Medical Center48
进行中（未招募）
1 期
Effect of Empagliflozin on Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 DiabetesPatients with Type 2 diabetes mellitusEUCTR2016-000172-19-DERWTH Aachen University for the Medical Faculty, represented by Center for Transitional & Clinical Research Aachen (CTC-A44
进行中（未招募）
1 期
Studying effects of medication (empagliflozin) in diabetes (or at risk of diabetes) and heart failureChronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2016-003719-37-GBHS Greater Glasgow and Clyde100
已完成
不适用
Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic controlType 2 diabetesJPRN-UMIN000018754Japan Society for Patient Report Outcome80
招募中
3 期
Effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parametersIRCT20190911044744N3Yazd University of Medical Sciences50